Niagen Bioscience
NAGE
169 hedge funds and large institutions have $205M invested in Niagen Bioscience in 2025 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 28 closing their positions.
25% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 28
13% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 54
4% more funds holding
Funds holding: 162 → 169 (+7)
0.53% more ownership
Funds ownership: 39.8% → 40.33% (+0.53%)
31% less capital invested
Capital invested by funds: $296M → $205M (-$91.3M)
60% less call options, than puts
Call options by funds: $1.23M | Put options by funds: $3.08M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.01M |
| 2 |
Morgan Stanley
New York
|
+$2.45M |
| 3 |
SEI Investments
Oaks,
Pennsylvania
|
+$2.42M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.5M |
| 5 |
Renaissance Technologies
New York
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.11M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.1M |
| 3 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$2.99M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$2.4M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$2.08M |
NAGE Hedge Fund Activity: Q4 2025 in Review
169 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2025, worth a combined $205M — down 31% from $296M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new NAGE positions and 28 closed out — a net gain of 7 holders — while 61 added to existing stakes and 54 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $4.01M. The largest seller was Vanguard Group, cutting an estimated $5.11M.
- 169 institutional investors held Niagen Bioscience (NAGE) as of Q4 2025, up from 162 in Q3 2025.
- Funds reported $205M of Niagen Bioscience stock for Q4 2025, down 31% quarter-over-quarter.
- 35 funds opened new Niagen Bioscience positions in Q4 2025 and 28 closed out, a net change of +7 holders.
- The largest Niagen Bioscience buyer in Q4 2025 was Goldman Sachs, an estimated $4.01M added.
- The largest Niagen Bioscience seller in Q4 2025 was Vanguard Group, an estimated $5.11M sold.
Based on aggregated 13F filings for Q4 2025.